ILMN — Illumina, Inc. stock price, charts and financials

QT72Illumina, Inc.

Illumina, Inc. (NASDAQ: ILMN) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
205.00
-6.06-2.87%
OverviewShort InterestFilings
ILMNQT72Illumina, Inc.·NASDAQ
205.00-2.87%
News
Down 2.9% — This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday (benzinga.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
WAT+0.47%$404.81LH-1.16%$321.10MTD-2.65%$1290.36DGX-0.02%$235.46IDXX-0.97%$515.15A-1.43%$144.75IQV-0.86%$256.98GH+1.12%$162.78
Snapshot
Index-P/E38.25EPS (ttm)5.36Insider Own3.24%Shs Outstand151.30MPerf Week-1.03%
Market Cap31.02BForward P/E33.75EPS next Y6.07Insider Trans-62.58%Shs Float147.74MPerf Month6.89%
Enterprise Value32.29BPEG2.78EPS next Q1.38Inst Own78.33%Short Float6.41%Perf Quarter28.10%
Income825.00MP/S6.90EPS this Y-0.14%Inst Trans0.00%Short Ratio4.87Perf Half Y67.55%
Sales4.49BP/B10.93EPS next Y13.48%ROA12.41%Short Interest9.46MPerf YTD56.30%
Book/sh18.76P/C26.56EPS next 5Y13.75%ROE31.08%52W High231.82 -11.57%Perf Year108.80%
Cash/sh7.72P/FCF35.16EPS past 3/5Y- 4.23%ROIC13.54%52W Low88.00 132.95%Perf 3Y25.21%
Dividend Est.-EV/EBITDA23.69Sales past 3/5Y-1.82% 6.02%Gross Margin66.79%Volatility3.95% 4.05%Perf 5Y-53.86%
Dividend TTM-EV/Sales7.19EPS Y/Y TTM169.70%Oper. Margin20.97%ATR (14)8.87Perf 10Y23.78%
Dividend Ex-Date-Quick Ratio1.40Sales Y/Y TTM2.77%Profit Margin18.36%RSI (14)48.18Recom2.58
Dividend Gr. 3/5Y-Current Ratio1.80EPS Q/Q10.08%SMA20-2.42%Beta1.43Target Price210.67
Payout0.00%Debt/Eq0.91Sales Q/Q9.65%SMA502.84%Rel Volume0.87Prev Close211.06
Employees8,600LT Debt/Eq0.73EarningsOct 29SMA20034.21%Avg Volume1.94MPrice205.00
IPO DateJul 28, 2000Option/ShortYes / YesEPS/Sales Surpr.6.82% 2.51%Net Debt/EBITDA1.09Volume1,689,247Change-2.87%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-09-26ReiteratedUBSNeutral$135 → $260
Sep-03-26ReiteratedArgus ResearchBuy$150 → $235
Aug-03-26ReiteratedCanaccord GenuityHold$190 → $205
Jul-31-26ReiteratedBernstein$185 → $215
Jul-31-26ReiteratedRBC CapitalOutperform$170 → $230
Jul-31-26ReiteratedGuggenheimBuy$200 → $226
Jul-31-26ReiteratedBarclaysUnderweight$122 → $160
Jul-17-26ReiteratedLeerink PartnersOutperform$250 → $210
Jul-14-26ReiteratedCanaccord GenuityHold$140 → $190
Jun-29-26ReiteratedGuggenheimBuy$180 → $200
Latest News· Times ET
Sep-09-26
Sep-09-2608:40AM
This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesdaybenzinga.com
Sep-08-26
Sep-08-2605:40PM
3 Stocks Soon Joining the S&P 500zacks.com
09:50AM
3 Promising Genomics Stocks in the Spotlight in 2026zacks.com
Sep-07-26
Sep-07-2609:01AM
Illumina (ILMN) Upgraded to Buy: What Does It Mean for the Stock?zacks.com
Sep-04-26
Sep-04-2603:15PM
Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600prnewswire.com
02:39PM
Bloom Energy, Illumina, Everpure Rise On S&P 500 Inclusioninvestors.com
08:51AM
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?Yahoo
04:51AM
Are Robots the New Normal? Bet on these ETFs to Invest in the Futurezacks.com
Sep-03-26
Sep-03-2610:10AM
The Market Just Told You Which Layer Of AI Biology It Is Paying Forglobenewswire.com
Sep-02-26
Sep-02-2608:04AM
Why Moderna's Cancer Vaccine Matters to Investorsetftrends.com
Aug-28-26
Aug-28-2603:45PM
$100 Invested In Illumina 20 Years Ago Would Be Worth This Much TodayBenzinga
05:10AM
Should You Add Illumina Stock to Your Portfolio Now?zacks.com
Aug-25-26
Aug-25-2603:15AM
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.247wallst.com
Aug-24-26
Aug-24-2612:04AM
Biondo Investment Advisors LLC Takes $1.87 Million Position in Illumina, Inc. $ILMNdefenseworld.net
Aug-23-26
Aug-23-2612:32AM
Allworth Financial LP Purchases New Position in Illumina, Inc. $ILMNdefenseworld.net
Company

Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.

Ownership
Total institutional ownership78.33%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/28/2025
FY 2024
12/29/2024
FY 2023
12/31/2023
FY 2022
1/1/2023
FY 2021
1/2/2022
FY 2020
1/3/2021
FY 2019
12/29/2019
FY 2018
12/31/2018
Total Revenue4,4934,3384,372——————
Cost of Goods Sold Incl. D&A1,4921,4451,511——————
Gross Profit3,0012,8932,861——————
Selling, General and Administrative Excl. Other1,1011,0781,092——————
Research and Development9589511,169——————
Other Operating Expense001,433——————
Operating Income942864-833——————
Interest Expense75101100——————
Unusual Expense
—————————
Non-Operating Income (Expense)148323-246——————
Net Income Before Taxes1,0151,086-1,179——————
Income Taxes19023644——————
Consolidated Net Income825850-1,223——————
Net Income From Continuing Operations825850-1,223——————
Net Income825850-1,223——————
EPS (Recurring)5.415.48-7.69——————
EPS (Basic, Before Extraordinaries)5.415.48-7.69——————
EPS (Diluted)5.365.45-7.69——————
EBITDA1,3631,457-725——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio38.2524.76———————
Price To Sales Ratio6.894.824.92——————
Gross Margin66.7966.6965.44——————
Operating Margin20.9719.92-19.05——————
Net Margin18.3619.59-27.97——————
Shares Outstanding151155159——————
Market Capitalization30,95520,91721,508——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$248.19$203.77$159.34$114.92$70.50● Close Price0.00M94.79M189.58M284.37M379.16MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Meister Keith A.DirectorSep 04 '26Sale218.40119,50126,098,466770,350Sep 04
Meister Keith A.DirectorSep 03 '26Sale218.2375,95116,574,482889,851Sep 04
Meister Keith A.DirectorSep 02 '26Sale213.2868,10814,526,255965,802Sep 04
Meister Keith A.DirectorAug 27 '26Sale228.89138,37931,673,7781,033,910Aug 27
Meister Keith A.DirectorAug 26 '26Sale225.46106,54324,021,2471,172,289Aug 27
Meister Keith A.DirectorAug 25 '26Sale225.51131,01929,546,6391,278,832Aug 27
Meister Keith A.DirectorAug 21 '26Sale217.96299,33665,243,4471,409,851Aug 21
Meister Keith A.DirectorAug 20 '26Sale213.86285,23861,000,1261,709,187Aug 21
Meister Keith A.DirectorAug 19 '26Sale203.2995,00019,312,8261,994,425Aug 21
Wedel Christensen JakobSVP, Strategy/Corp DevelopmentAug 18 '26Sale191.521,033197,84014,023Aug 20
Meister Keith A.DirectorAug 05 '26Sale199.61283,26956,543,3322,089,425Aug 06
Meister Keith A.DirectorAug 04 '26Sale200.10457,85891,616,5652,372,694Aug 06
Davies Scott MChief Legal OfficerJul 30 '26Sale200.00615123,00020,338Aug 03
Davies Scott MChief Legal OfficerJun 25 '26Sale180.00615110,70020,953Jun 25
Leckman PatriciaSVP, Chief People OfficerJun 05 '26Sale162.59783127,30521,259Jun 09
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.